<DOC>
	<DOCNO>NCT01158898</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , 3-way crossover trial evaluate efficacy safety two different dos inhale TPI ASM8 administer daily 14 day treatment allergic asthma allergen-induced asthma .</brief_summary>
	<brief_title>Efficacy TPI ASM8 During 14-Day Allergen Challenge</brief_title>
	<detailed_description>Two dos TPI ASM8 compare placebo look effect asthmatic response allergen challenge 3-way cross design . Sputum inflammation , mRNA gene expression target receptor , ECP , biomarkers mast cell activation et PK profile study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Mild asthma , male female age 1855 y.old Steroidnaive , nonsmoker Dual responders Any chronic disease ( unstable ) Immunosuppressed , recent ongoing steroid intake Methacholine PC 20 &gt; 16 mg/mL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Mild moderate asthma</keyword>
	<keyword>Allergen inhalation challenge</keyword>
</DOC>